➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Johnson and Johnson
Moodys
Mallinckrodt
Colorcon

Last Updated: January 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for ABX464

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for ABX464?

ABX464 is an investigational drug.

There have been 12 clinical trials for ABX464. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2020.

The most common disease conditions in clinical trials are Colitis, HIV Infections, and Ulcer. The leading clinical trial sponsors are Abivax S.A., FLS-RS, and [disabled in preview].

There are eleven US patents protecting this investigational drug and two hundred and six international patents.

Recent Clinical Trials for ABX464
TitleSponsorPhase
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19Abivax S.A.Phase 2/Phase 3
Study Evaluating the One-Year Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid ArthritisAbivax S.A.Phase 2
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative ColitisAbivax S.A.Phase 2

See all ABX464 clinical trials

Clinical Trial Summary for ABX464

Top disease conditions for ABX464
Top clinical trial sponsors for ABX464

See all ABX464 clinical trials

US Patents for ABX464

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ABX464   Start Trial Compounds useful for treating AIDS ABIVAX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR)   Start Trial
ABX464   Start Trial Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging ABIVAX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR)   Start Trial
ABX464   Start Trial Treatments to eliminate HIV reservoirs and reduce viral load INSTITUT PASTEUR (Paris, FR)   Start Trial
ABX464   Start Trial Quinoline derivative for use in the treatment and prevention of viral infections ABIV AX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR)   Start Trial
ABX464   Start Trial Quinoline derivatives for the treatment of inflammatory diseases ABIVAX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR)   Start Trial
ABX464   Start Trial Process for preparing quinolin-2-yl-phenylamine derivatives and their salts RATIOPHARM GMBH (Ulm, DE)   Start Trial
ABX464   Start Trial Compounds useful for treating cancer ABIVAX (Paris, FR) CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE MONTPELLIER 2 (Montpellier, FR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ABX464

Drugname Country Document Number Estimated Expiration Related US Patent
ABX464 Australia AU2010258214 2029-06-12   Start Trial
ABX464 Australia AU2010258294 2029-06-12   Start Trial
ABX464 Australia AU2010258295 2029-06-12   Start Trial
ABX464 Australia AU2015203256 2029-06-12   Start Trial
ABX464 Australia AU2017202500 2029-06-12   Start Trial
ABX464 Australia AU2019203896 2029-06-12   Start Trial
ABX464 Brazil BR122019013686 2029-06-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Johnson and Johnson
Moodys
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.